Cyclin E1 molecular glue degraders (MGDs) represent a potential novel therapeutic approach by directly and selectively targeting a frequently amplified non-enzymatic driver oncogene relevant in ...
BMI1 is a member of the Polycomb group family of transcriptional repressors that was originally identified as an oncogenic partner of c-Myc in murine lymphomagenesis (Haupt et al., 1991; van Lohuizen ...
(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), Monday announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial evaluating azenosertib in Cyclin E1+ ...
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial A large-panel gene ...
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...
Yan Geng, Qunyan Yu, Wendy Whoriskey, Fred Dick, Kenneth Y. Tsai, Heide L. Ford, Debajit K. Biswas, Arthur B. Pardee, Bruno Amati, Tyler Jacks, Andrea Richardson, Nicholas Dyson, Piotr Sicinski ...
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (GLUE) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results